Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs.
The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and -- together with the previous volumes -- constitutes the first systematic approach to drug analogue development.Content:
Chapter 1 Pioneer and Analogue Drugs (pages 1โ19): Prof. Dr. Janos Fischer, Prof. Dr. C. Robin Ganellin and Prof. Dr. David P. Rotella
Chapter 2 Competition in the Pharmaceutical Drug Development (pages 21โ35): Christian Tyrchan and Fabrizio Giordanetto
Chapter 3 Metabolic Stability and Analogue?Based Drug Discovery (pages 37โ75): Amit S. Kalgutkar and Antonia F. Stepan
Chapter 4 Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders (pages 77โ110): Dr. Mark L. Peterson, Dr. Hamid Hoveyda, Dr. Graeme Fraser, Eric Marsault and Rene Gagnon
Chapter 5 The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes (pages 111โ139): A. Ganesan
Chapter 6 Thienopyridyl and Direct?Acting P2Y12 Receptor Antagonist Antiplatelet Drugs (pages 141โ164): Dr. Joseph A. Jakubowski and Atsuhiro Sugidachi
Chapter 7 Selective Estrogen Receptor Modulators (pages 165โ185): Amarjit Luniwal, Rachael Jetson and Paul Erhardt
Chapter 8 Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists (pages 187โ209): Kazumi Kondo and Hidenori Ogawa
Chapter 9 The Development of Cysteinyl Leukotriene Receptor Antagonists (pages 211โ239): Peter R. Bernstein
Chapter 10 The Discovery of Dabigatran Etexilate (pages 241โ267): Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn and Wolfgang Wienen
Chapter 11 The Discovery of Citalopram and Its Refinement to Escitalopram (pages 269โ294): Klaus P. Bogeso and Connie Sanchez
Chapter 12 Tapentadol โ From Morphine and Tramadol to the Discovery of Tapentadol (pages 295โ318): Helmut Buschmann
Chapter 13 Novel Taxanes: Cabazitaxel Case Study (pages 319โ341): Dr. Herve Bouchard, Dr. Dorothee Semiond, Dr. Marie?Laure Risse and Dr. Patricia Vrignaud
Chapter 14 Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure?Based Drug Design (pages 343โ363): Srikanth Venkatraman, Andrew Prongay and George F. Njoroge
Chapter 15 A New?Generation Uric Acid Production Inhibitor: Febuxostat (pages 365โ376): Ken Okamoto, Shiro Kondo and Takeshi Nishino